ライフサイエンスコーパス: siRNA

1 siRNA is complexed onto a NaYF4:Yb/Tm/Er UCNP through an

2 siRNA knockdown of ANLN blocked cytokinesis in H2.35 liv

3 siRNA knockdowns and inhibitor experiments demonstrated

4 siRNA mediated silencing of Cofilin/ADF provokes strikin

5 siRNA targeting CaMKIIalpha reversed established mechani

6 siRNA-L2, in comparison with unmodified siRNA, exhibited

7 siRNA-mediated depletion of AKAP350A caused displacement

8 siRNA-mediated depletion of GNB1 (encoding Gbeta1) in mu

9 siRNA-mediated knockdown of cathepsin B in McA-RH7777 ce

10 siRNA-mediated loss of RP2 or Arl3 reduced the level of

11 siRNA-mediated LPP silencing in ovarian tumor-bearing mi

12 siRNA-mediated spl suppression resulted in effects oppos

13 siRNAs were delivered to LAP-MYC mice, which develop hep

14 uced by VEGF had no effect in either HSP70-1 siRNA in vitro or HSP70-1 knockout mice.

15 teine, the ERK1/2 inhibitor UO126, or ERK1/2 siRNA knockdown blocked the H2O2-induced shift of MLK3,

16 umbilical ECs (HUVEC) treated with Kindlin-2 siRNA showed enhanced basal and platelet-activating fact

17 Treatment with PEI+TSP-2 siRNA significantly suppressed TSP-2 gene expression (3.

18 the following: polyethylenimine (PEI)+TSP-2 siRNA, saline, PEI only, or PEI+control siRNA.

19 rogated PKD1 phosphorylation at Ser(203), 2) siRNA-mediated knockdown of PAK1 and PAK2 in IEC-18 and

20 er, experiments with Kv1.3 KO rats and Kv1.3 siRNA knockdown or channel-specific inhibition of human

21 hese results were further verified by CDK4/6 siRNA knockdown.

22 A siRNA knockdown of HSP70-1 suppressed angiogenic respons

23 The study used a siRNA against the chemoresistance gene survivin and two

24 derived from an affected individual and ACTB siRNA knockdown in wild-type fibroblasts showed altered

25 d RDR6 and of the endogenous virus-activated siRNAs by RDR1.

26 targeted delivery of therapeutically active siRNAs to hepatocytes in vivo.

27 e engineered a series of ultra-high affinity siRNA binders based on the viral protein p19 and develop

28 An siRNA-mediated knockdown of Mule or TRIM26 leads to stab

29 lived endogenous serum protein albumin as an siRNA carrier.

30 with the structural data, modification of an siRNA with (S)-GNA resulted in greater in vitro potencie

31 In this study, we performed an siRNA-based screen of the kinome to identify genetic reg

32 We furthermore present an siRNA off-target discovery pipeline that not only predic

33 igh-throughput functional assay to screen an siRNA library targeting 6,650 different cellular protein

34 rapy using a nanoparticle formulated with an siRNA against CX3CL1 reduced Ly6Clo monocyte recruitment

35 Compared with an siRNA-like approach, the requirement of perfect compleme

36 neurokinin-1 (NK-1) receptor antagonists and siRNA inhibits TNF secretion by 50% (P < 0.001) when sti

37 Co-delivery of both chemotherapy drugs and siRNA from a single delivery vehicle can have a signific

38 The pharmacologic MLCK inhibition and siRNA-induced knock-down of MLCK inhibited the LPS-induc

39 njunction with small-molecule inhibitors and siRNA gene silencing, cathepsin S was identified as the

40 Small molecule inhibitors and siRNA knockdown of both ADAM proteases confirmed these r

41 ls, showed elevated SNX9 protein levels, and siRNA-mediated knockdown of SNX9 in XLKO Ocy454 cells pr

42 ances differentiation, while morpholino- and siRNA-induced knockdown diminishes it.

43 th cytoplasmic activity such as the mRNA and siRNA or nuclear diffusible oligonucleotide.

44 L), an epithelial targeting peptide (P) and siRNA (R).

45 he small interfering RNA (siRNA) pathway and siRNA from a family of X-linked satellite repeats (1.688

46 f nucleic acids, both plasmid DNA (pDNA) and siRNA, to treat localised disease or provide vaccination

47 ases as in vivo binding partners of Rev, and siRNA experiments indicated a functional role for many i

48 ent kinase inhibition (using roscovitine and siRNA directed towards cyclin-dependent kinase 5) amelio

49 lementation with exogenous CNTF in vitro and siRNA knockdown in vivo.

50 iated signaling pathways with inhibitors and siRNAs, we found that the MAPK-JNK pathway was involved

51 Ultrasound can be used to deliver mRNAs and siRNAs to the colonic mucosa of mice and knock down expr

52 Treatment of RPE cells with AnxA8 siRNA recapitulated exposure to FR, with cell cycle arre

53 e or activation of biomacromolecules such as siRNA remains a significant challenge.

54 functionalized with PEG (i.e., UCNP-(CD/Azo)-siRNA/PEG NPs), targeting ligands (i.e., EGFR-specific G

55 to-UV upconversion nanoparticle (UCNP)-based siRNA nanocarrier for NIR-controlled gene silencing.

56 onal stabilization in the 5'-regions of both siRNA strands significantly enhances the overall metabol

57 Targeted inhibition of ATM by siRNA attenuated the ability of XWL-1-48 on inducing DNA

58 mRNA level was reduced upon p62 deletion by siRNA and increased with p62 overexpression in breast ca

59 TCTP was knocked down by siRNA or overexpressed by plasmid transfection.

60 herapeutic targeting of endothelial FABP4 by siRNA in vivo has antiangiogenic and antitumour effects

61 small interfering RNA (siRNA) is hampered by siRNA's comprehensively poor pharmacokinetic properties,

62 JB12 knockdown by siRNA led to the induction of caspase processing but not

63 Hsp90 knockdown by siRNA or by Hsp90 active-site mutation also decreased A3

64 Ablation of Mdm2 by siRNA led to an increase in p53 protein and repression o

65 FR1(+) myeloid cells, which were reversed by siRNA or pharmacological inhibition of STAT3.

66 hen its protein expression was suppressed by siRNA in both Melan-a and B16-F10 cells.

67 ion of integrin-beta, Arp2/3 and vinculin by siRNA significantly attenuated the myosin-X-induced long

68 MPA; however, silencing their expression by siRNAs could enhance the inhibitory effect of MPA on HCV

69 itive and reversed by okadaic acid or PP2A-C siRNA.

70 Importantly, CcnE1-siRNA also prevented progression of liver fibrosis if ap

71 Pretreatment with CcnE1-siRNA reverted CcnE1 induction to baseline levels of hea

72 Treating rat OPCs with cGSN siRNA reduced OPC differentiation, whereas overexpressio

73 of immature seed coats demonstrated that CHS siRNA levels cause the patterns produced by the i(i) and

74 lleles leads to altered distributions of CHS siRNAs, thus explaining how the k1 mutation reverses the

75 -derived macrophages (BMDMs), CLIC1 or CLIC4 siRNA transfection impaired transcription of IL-1beta, A

76 Benchmarked against leading commercial siRNA nanocarrier in vivo jetPEI, siRNA-L2 achieved 19-f

77 nt N-acetylgalactosamine (GalNAc)-conjugated siRNA in mice relative to the un-modified siRNA.

78 ances the efficacy of cholesterol-conjugated siRNAs and the duration of silencing in vivo.

79 ion of fully modified cholesterol-conjugated siRNAs increases their potency and efficacy in vitro, bu

80 escein isothiocyanate (FITC)-labeled control siRNA delivered intranasally was found in the cytoplasm

81 SP-2 siRNA, saline, PEI only, or PEI+control siRNA.

82 The challenge has been to deliver siRNA to the lung with sufficient efficacy for a sustain

83 eless, few studies have used DNPs to deliver siRNAs in vivo, and none has demonstrated therapeutic ef

84 tures, iRGD-targeted nanoparticles delivered siRNA directed against TNFalpha in a receptor-specific f

85 tively, our data suggest that AGO4-dependent siRNAs are secondary siRNAs dependent on the prior activ

86 In summary, these data demonstrate effective siRNA transfection of the injured arterial wall and prov

87 ent endosomal/lysosomal escape and efficient siRNA decomplexation inside the target cells was develop

88 scale implementable device to deliver either siRNAs or small molecule inhibitors in vivo, we showed t

89 e bulk-cultured population, CSLC-eliminating siRNAs were enriched in a few functional categories, suc

90 al fertility and acts as an effector of endo-siRNAs.

91 s required for biogenesis of many endogenous siRNAs in Drosophila In vitro, Loqs-PD enhances the rate

92 ed by eNOS inhibitor L-NAME or specific eNOS siRNA in H2O2-treated cells.

93 ost strongly down-regulated by Etv4 and Etv5 siRNAs.

94 However, for exogenous siRNAs it is limited by the rapid removal of the 5- phos

95 Finally, siRNA knockdown of LRRC8C+LRRC8D strongly inhibited the

96 Following siRNA screening of 47 upregulated proteins indicated tha

97 rease in paracellular permeability following siRNA-mediated suppression of TJ transcripts, claudin-11

98 Unexpectedly, morc-1 is dispensable for siRNA inheritance but is required for target silencing a

99 self-assembling nanocomplex formulation for siRNA delivery to the airways that consists of a liposom

100 Here, the authors utilize a nanocarrier for siRNA for treatment of arteries ex vivo prior to implant

101 s of short RNAs that serve as precursors for siRNAs targeting non-identical members of transposon fam

102 Further, siRNA knockdown of endogenous GATAD2B significantly redu

103 es the overall metabolic stability of GalNAc-siRNA conjugates.

104 The GE11-conjugated, GFP-siRNA-complexed NPs exhibited excellent GFP gene silenci

105 putes the off-targeting potential of a given siRNA.

106 ssues, compared with mice with colitis given siRNA against Tnf mRNA without ultrasound (P </= .014),

107 Some mice were given siRNA against tumor necrosis factor (Tnf) mRNA for 6 day

108 ed both in Herpud1-knockout mice and Herpud1 siRNA-treated rat cardiomyocytes.

109 HES1 siRNA treatment early in differentiation increased CLDN1

110 ol IV), and ARGONAUTE4 (AGO4) is a major het-siRNA effector protein.

111 The accumulation of AGO4-dependent het-siRNAs also requires several factors known to participat

112 The biogenesis of most het-siRNAs depends on the plant-specific RNA polymerase IV (

113 or the accumulation of a small subset of het-siRNAs.

114 Phenotypic modifications of irradiated, Hey2 siRNA- and Hey2 vector plasmid-transfected human umbilic

115 precursors of highly abundant viral and host siRNAs by the cellular RdRPs.

116 nsdermal delivery of erlotinib and IL36alpha siRNA as a potential dual therapy for psoriasis.

117 nsdermal delivery of erlotinib and IL36alpha siRNA by CYnLIP efficaciously treated psoriatic-like pla

118 In siRNA-MUC4 BEAS-2B airway epithelial cells dexamethasone

119 iNOS siRNA and 1400W, a selective iNOS inhibitor, abolished t

120 Interestingly, siRNAs that selectively reduced CSLC only were found to

121 sed therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides

122 he viral protein p19 and developed them into siRNA carriers targeted to the epidermal growth factor r

123 commercial siRNA nanocarrier in vivo jetPEI, siRNA-L2 achieved 19-fold greater tumor accumulation and

124 JNK was suppressed by SP600125 or Jnk siRNA.

125 e-differentiation which was reversed by KLF5 siRNA.

126 -MYC proteins were decreased after LINC00152 siRNA treatment.

127 uman ovarian cancer, a nanoparticle-mediated siRNA strategy to target DANCR in vivo was sufficient to

128 ogenesis does not rely on canonical microRNA/siRNA processing machinery (i.e., independent of DICER-L

129 Both MLK3 siRNA knockdown and FLAG-MLK3-S705A-S758A expression dec

130 n cancer cells, which was attenuated by MLK3 siRNA knockdown.

131 directly and indirectly by shoot-root mobile siRNAs are associated with different histone modificatio

132 Long-distance, shoot-root, mobile siRNAs influence DNA methylation in recipient tissues 54

133 amine (GalNAc) ligand to chemically modified siRNA has enabled asialoglycoprotein (ASGPR)-mediated ta

134 ed siRNA in mice relative to the un-modified siRNA.

135 ved binding affinity of the 5-E-VP -modified siRNA to human Argonaute-2 in-vitro, as well as the enha

136 chemically stabilized, cholesterol-modified siRNAs (sd-rxRNAs((R))) that efficiently enter cells and

137 d siRNA conjugated to a diacyl lipid moiety (siRNA-L2), which rapidly binds albumin in situ.

138 MSMP siRNA, delivered in vivo using the DOPC nanoliposomes, r

139 he issues regarding to the delivery of naked siRNA predominantly to target cells.

140 LPRs, containing 50 nM or 100 nM siRNA, showed high levels of silencing, particularly in

141 therapeutic strategy that involves nonviral siRNA delivery to ameliorate the response to vascular in

142 fected with MARV or RAVV and treated with NP siRNA-LNP, with MARV-infected animals beginning treatmen

143 cestor of land plants, but the 24-nucleotide siRNA pathway that guides DNA methylation is incomplete

144 NAs (siRNAs) and low-abundance 22-nucleotide siRNAs produced from double-stranded RNA (dsRNA) by DCL4

145 s produced more DCL2-dependent 22-nucleotide siRNAs than the wild type and showed enhanced systemic m

146 Consistent with the observation, siRNA-mediated IKK2 knockdown decreased GR down-regulati

147 Binding of siRNA to PEI-polymer was characterized and confirmed by

148 he DDB2-AGO1 complex is under the control of siRNA abundance and DNA damage signaling.

149 esicles were capable of specific delivery of siRNA to cells, and efficiently blocked tumour growth in

150 -targeted, nanoparticle-mediated delivery of siRNA to VS and establish a novel platform for the devel

151 was developed for tumor-targeted delivery of siRNA.

152 siRNA binding could prevent the discharge of siRNA from its carrier, higher affinity continually led

153 gnificantly affect the intracellular fate of siRNA and may serve as a handle for improving the effici

154 ired for target silencing and maintenance of siRNA-dependent chromatin organization.

155 Protein-based methods of siRNA delivery are capable of uniquely specific targetin

156 nucleic acid analogue, as a modification of siRNA duplexes.

157 The improved pharmacokinetic properties of siRNA-L2 facilitated significant tumor gene silencing fo

158 approximately 27.3), complete protection of siRNA from early enzymatic degradation was observed.

159 f azobenzene, thus leading to the release of siRNA due to unmatched host-guest pairs.

160 Conjugation of siRNAs to lipophilic groups supports efficient cellular

161 oxicity, efficient intracellular delivery of siRNAs and the protection of siRNAs from premature degra

162 not detected, but intracameral injection of siRNAs targeting ZO-1 and tricellulin increased outflow

163 5-Vinylphosphonate modification of siRNAs protects them from phosphatases, and improves sil

164 be useful modifications for optimization of siRNAs.

165 for optimization of biological properties of siRNAs.

166 lar delivery of siRNAs and the protection of siRNAs from premature degradation before reaching the ta

167 amide linkage throughout the guide strand of siRNAs.

168 We used three types of siRNAs (NP-717, NP-1155 and NP-1496) in encapsulated for

169 Overexpression of miR-124 or siRNA silencing of PTPB1 restored normal proliferation a

170 blockade of the receptors with antibodies or siRNA knockdown decreased the uptake of Mtb.

171 e Complex 2) by pharmaceutical inhibition or siRNA reduced the levels of H3K27me3 and induced cardiog

172 NA for shorter nucleic acids such as mRNA or siRNA.

173 the Nae1 inhibitor MLN4924 (Pevonedistat) or siRNA against nedd8 in early or late stages of different

174 Our siRNA knockdown experiments on ProGENI-identified genes

175 assay, treatment of HC11-Int3 cells with P50-siRNA caused a significant decrease in colony formation.

176 ity which was reversed by Robo4 and Paxillin siRNA.

177 Conjugated peptides and peptide/siRNA complexes did not show significant cytotoxicity in

178 At peptide:siRNA weight/weight ratio of 10:1 (N/P approximately 13.

179 PID1 siRNA diminished cisplatin-induced apoptosis, suggesting

180 eLa cells, we have observed polyethylenimine/siRNA polyplexes initially appearing in early endosomes

181 gel particles can be considered as promising siRNA carriers for in vivo purposes towards therapeutic

182 PTBP1 gene knockdown was achieved via PTBP1-siRNA; restoration of miR-124 was performed with miR-124

183 sphorylation, which can be restored by PTP1B siRNA.

184 Aortic discs isolated from PTP1B siRNA-transfected mice also had augmented endothelial ou

185 bovine aortic endothelial cells, while PTP1B siRNA increased both, implicating negative regulation of

186 Endothelial cells transfected with PTP1B siRNA showed faster wound closure in response to VEGF.

187 but clear involvement of SAC3B in regulating siRNAs and DNA methylation, particularly at a group of T

188 Remarkably, siRNA-L2 achieved a tumor:liver accumulation ratio >40:1

189 ipoplex, a complex of small interfering RNA (siRNA) and cationic liposomes.

190 t the majority of the small interfering RNA (siRNA) clusters had a higher expression level in the F1

191 of therapies based on small interfering RNA (siRNA) is hampered by siRNA's comprehensively poor pharm

192 In addition, small interfering RNA (siRNA) knockdown studies suggested that nonclassical tar

193 cells, we performed a small interfering RNA (siRNA) library screen targeting the 58 human DEAD-box RN

194 omyocytes with either small interfering RNA (siRNA) or Mdivi-1 caused marked reduction in virus produ

195 demonstrated that the small interfering RNA (siRNA) pathway and siRNA from a family of X-linked satel

196 egulation of ROCK1 by small interfering RNA (siRNA) selectively reduced the colony-forming ability of

197 In this study, small interfering RNA (siRNA)-based screening of approximately 4800 druggable g

198 PAF1 repressing AGO1/small interfering RNA (siRNA)-directed silencing [13, 14] and Drosophila PAF1 o

199 protein acetylation, small interfering RNA (siRNA)-mediated HDAC5 knockdown did not alter the acetyl

200 Interestingly, small interfering RNA (siRNA)-mediated knockdown of GPR64 in hESCs remarkably r

201 Importantly, small interfering RNA (siRNA)-mediated knockdown of NAP1L1, Bin1 or VAP-A impai

202 ogic PLK1 inhibitors, small interfering RNA (siRNA)-mediated knockdown, and overexpression of constit

203 ter OPN4 knockdown by small interfering RNA (siRNA).

204 ated protein 7 (Atg7) small interfering RNA (siRNA).

205 nterference for MUC4 (small interfering RNA [siRNA]-MUC4) was used to analyze the role of MUC4 in the

206 d using inhibitor or small interfering RNAs (siRNAs) against caveolin-1 or Tie2 inhibited their traff

207 nflammatory drugs or small interfering RNAs (siRNAs) against COX-1 and COX-2, significantly reduced P

208 undant 21-nucleotide small interfering RNAs (siRNAs) and low-abundance 22-nucleotide siRNAs produced

209 ide or 24-nucleotide small interfering RNAs (siRNAs) generated from previously silenced regions of th

210 al Genome Repair and small interfering RNAs (siRNAs) in the recognition of DNA photoproducts, prevale

211 cations of synthetic short interfering RNAs (siRNAs) require chemical modifications.

212 d color by producing small interfering RNAs (siRNAs) targeting chalcone synthase (CHS) mRNAs.

213 n precisely generate small interfering RNAs (siRNAs) that are active in the RNA-induced silencing com

214 rgeting GADD45B with short interfering RNAs (siRNAs), as with miR-K9.

215 In studies using small interfering RNAs (siRNAs), responses to AR were significantly decreased in

216 d for reduced tissue accumulation and robust siRNA delivery in vitro and in vivo.

217 Loss-of-function studies show that Rpn11-siRNA knockdown decreases MM cell viability.

218 ed in CVB3 S100A8 knockdown versus scrambled siRNA CVB3 cells.

219 A secondary siRNA screen of the identified signaling factors reveale

220 est that AGO4-dependent siRNAs are secondary siRNAs dependent on the prior activity of the RdDM pathw

221 These effects were ablated with selective siRNA silencing of these proteins.

222 We found that several siRNA-generating mechanisms all trigger de novo expressi

223 These results identify a single siRNA therapeutic that provides broad-spectrum protectio

224 duced in chondrocytes transfected with SIRT1 siRNA or treated with nicotinamide (NAM), a sirtuin inhi

225 Sp1 siRNA treatment reduced mRNA and protein expression of S

226 Utilizing specific siRNAs we observed that LLC cell-conditioned medium (LCM

227 ts TNF secretion by 50% (P < 0.001), and ST2 siRNA decreases TNF secretion by 30% (P < 0.05), when st

228 Despite concerns that excessively strong siRNA binding could prevent the discharge of siRNA from

229 mOGT is also critical for cell survival; siRNA-mediated knockdown of endogenous mOGT protected ce

230 c membrane antigen, and loaded with survivin siRNA, inhibited prostate cancer xenograft.

231 We synthesized siRNA conjugated to a diacyl lipid moiety (siRNA-L2), wh

232 tely suppressed using chemically synthesized siRNAs.

233 have become an attractive tool for systemic siRNA delivery, but improvement of their in vivo toleran

234 n the germline, and, through TAS3-derived ta-siRNA, restricted ARF3 expression to the medio domain of

235 rived trans-acting small interfering RNA (ta-siRNA), which represses ARF3 expression.

236 on into lateral epidermal cells in a TAS3 ta-siRNA-insensitive mutant led to the formation of supernu

237 In addition, miRNAs and ta-siRNAs are also involved in the plant responses to abiot

238 and trans-acting small interfering RNAs (ta-siRNAs) mainly inhibit gene expression at post-transcrip

239 uld be a promising nanoplatform for targeted siRNA delivery to EFGR-overexpressing cancer cells.

240 s patients and transfected with SNP-targeted siRNA, using glucan particles taken up by phagocytosis.

241 the improved efficacy of using LPP-targeting siRNA in combination with cytotoxic drugs.

242 knockdown by SNAs composed of MGMT-targeting siRNA duplexes (siMGMT-SNAs).

243 ingle nucleoprotein-targeting (NP-targeting) siRNA in nonhuman primates at advanced stages of MARV or

244 Ternary siRNA polyplexes were assembled with varied amounts and

245 Over 80% of multiple-tested siRNAs and shRNAs targeting CD95 or CD95 ligand (CD95L)

246 We also found that siRNA knockdown of SIRT3 or SOD2 increased NLRP3 superco

247 Intracellular tracking studies revealed that siRNA delivered by unimolecular NPs was efficiently rele

248 In addition, we show that siRNA-mediated knockdown of the transcription factor SPT

249 finity dependence of silencing suggests that siRNA-carrier affinity can significantly affect the intr

250 The siRNA delivered by the DNPs inhibited cell growth both i

251 The siRNA-L2 tumor accumulation diminished only twofold, sug

252 internalization of Lipoplex, diminished the siRNA concentration in RISC, and retarded the mRNA knock

253 employing the hybrid microcontainers for the siRNA encapsulation we demonstrate the reduction of vira

254 Intranasal delivery of the siRNA targeting Beclin1 significantly depleted the targe

255 We propose that the siRNA pathway promotes X recognition by enhancing the ab

256 Northern blot analysis detected the siRNAs products in virus-free transgenic papaya tissue c

257 rafts were markedly inhibited by therapeutic siRNA delivery targeting mouse endothelial FABP4.

258 ols for the systemic delivery of therapeutic siRNA and have great potential for further clinical tran

259 clease resistance and potency of therapeutic siRNAs by introducing 4'-C-methoxy (4'-OMe) as the alpha

260 Through siRNA knock-down of NeoR, we improved the production- an

261 d that dsRNA is transported and processed to siRNAs by EAB larvae within 72 h after ingestion.

262 digestion by dsRNases and its processing to siRNAs in the cells are among the major factors contribu

263 knockdown of Notch3 expression by transient siRNA transfection promoted the expression of osteogenic

264 Here, we compared two siRNAs of the same sequence but with different modificat

265 The UCNP-siRNA complexes are also functionalized with PEG (i.e.,

266 litis, ultrasound delivery of unencapsulated siRNA against Tnf mRNA reduced protein levels of TNF in

267 siRNA-L2, in comparison with unmodified siRNA, exhibited a 5.7-fold increase in circulation half

268 e oscillations were strongly attenuated upon siRNA-mediated clock disruption in human primary myotube

269 2-dependent intron retention is induced upon siRNA knock-down of SMN in HeLa cells.

270 e exosome release pathways involved, we used siRNA to suppress expression of ESCRT (endosomal sorting

271 Using siRNA in HeLa cells, we found that reducing endogenous m

272 Further analysis using siRNA knockdown techniques against several of these prot

273 CAF1 in untransformed epithelial cells using siRNA was sufficient to recapitulate the increased motil

274 (MPP), and selective knockdown of ESR1 using siRNA decreased VEGFA and prevented the ability of E2 to

275 Furthermore using siRNA-induced in vivo knockdown approach we demonstrated

276 Here, using siRNA-mediated knockdown of KIF20B in a human cell line

277 om severe asthmatics and PP5 knockdown using siRNA restored fluticasone repressive action on chemokin

278 Silencing of NRF2 using siRNA diminished the protective effects of melatonin, wh

279 Using siRNAs to type I and II BMP receptors and the signaling

280 n addition, AR gene expression knockdown via siRNA greatly inhibited cell growth and viability.

281 emplate de novo synthesis of secondary viral siRNAs (vsRNA), which are secreted in exosome-like vesic

282 ed to enhance the amplification of the viral siRNAs by RNA-dependent RNA polymerase (RdRP) 1 (RDR1) a

283 Additionally, using a targeted in vitro siRNA approach, we examined whether knock-down of TTP ca

284 sulting in robust endosomolysis and in vitro siRNA silencing ( 85% protein level knockdown) of the mo

285 In vitro, siRNA-mediated FABP4 knockdown in endothelial cells led

286 d LPS-induced macrophage activation, whereas siRNA-mediated knockdown of TRIM59 enhanced LPS-induced

287 Our high-throughput genome-wide siRNA screen identified host factors that prevent reprod

288 , we performed a viability-based genome-wide siRNA screen in HeLa cells.

289 Using genome-wide siRNA screening, we have identified prohibitin (PHB) as

290 In this study, we used a kinome-wide siRNA screen to identify kinases that, when downregulate

291 ll the peptides showed complete binding with siRNA, and at a w/w ratio of 20:1 (N/P approximately 27.

292 ctroscopy showed effective complexation with siRNA as well as its release upon particle degradation a

293 erse changes in WWOX transcripts levels with siRNA interference eliminating PARTICLEs elevated transc

294 Suppression of PGC-1beta and PRC with siRNA reverses the effects of IGF-1 and disrupts mitocho

295 cells and fibroblasts were transfected with siRNA targeting Apaf-1.

296 was also observed in cells transfected with siRNA targeting VCP.

297 erse biologic processes were associated with siRNAs reducing the bulk-cultured population, CSLC-elimi

298 ficantly decreased in cells transfected with siRNAs against epithelial sodium channel ENaCalpha or EN

299 Unlike knock-out of individual ZDHHCs, siRNA-mediated knockdown of both ZDHHC3 and ZDHHC7 in ZD

300 ding homeobox 1 transcription factor (ZEB1), siRNA-mediated knockdown and overexpression experiments